創益生技股份有限公司

Banner Up

Body Conditioning

Health Food Certificate

敏自寧

L. j EM                 
Ministry of Health and Welfare Food No. A00141
Improving Allergic Body Conditions
  • Validated by animal trials: 
    1. Effective reduce the production of allergy related IL-5 protein. 
    2. Effective increase speed growth and regeneration.
 
Research  Collaboration  Results
28 days animal feed safety assessment  National Taiwan University College of Medicine Graduate Institute of Toxicology  The no-observed-adverse-effect-level (NOAEL) is 4.2g/kg. This dosage is 100 times the recommended dosage for human consumption.
Genotoxicity assessment  National Taiwan University College of Medicine Graduate Institute of Toxicology  Negative for gene mutation analysis.
In vivo micronucleus assay  National Taiwan University College of Medicine Graduate Institute of Toxicology  Negative for micronucleus in rodents.
Improving allergic body conditions- mice trials  Food Industry Research and Development Institute  Effective in reducing allergy related IL-5 secretion and increasing spleen growth.
 

舒敏佳Comprobi®

L. r MP108                 
Ministry of Health and Welfare Food No. A00271
Improving Allergic Body Conditions
Validated by animal trials: 
1. Effective in reducing allergy related IgE antibody production. 
2. Effective in relieving respiratory tract hypersensitivity. 
3. Aid in the regulation of Th1/Th2cytokine.
 
Research  Collaboration  Results
Rat oral acute toxicity trial  Super Laboratory Co., Ltd.               No visually observable pathological changes.
28 days animal feed safety assessment  Super Laboratory Co., Ltd.  The no-observed-adverse-effect-level (NOAEL) is 1,000 mg/kg/day. This dosage is 125 times the recommended dosage for human consumption.
Genotoxicity assessment  Super Laboratory Co., Ltd.  Negative for gene mutation analysis.
In vivo micronucleus assay  Super Laboratory Co., Ltd.  Negative for micronucleus in rodents.
In vitro mammalian chromosome aberration test  Super Laboratory Co., Ltd.  Negative test response.
Lactobacillus rhamnosustrain typing sequencing analysis  Food Industry Research and Development Institute  Lactobacillus rhamnosusMP108 exhibited different dnaK and mutL sequences than 6 other known strains, which can be used for strain-typing as a specific strain.
Improving allergic body conditions- mice trials  Taipei Medical University  1. Effective in reducing allergy related IgE antibody production. 
2. Effective in reliving respiratory tract hypersensitivity. 
3. Aid in the regulation of Th1/Th2 cytokine.
 

天天佳An-Ti Allergy®

L. paracasei                  
Ministry of Health and Welfare Food No. A00232
Immunological Regulation
1.Effective in promoting IgG production. 
2.Effective in regulating T cell cytokine.
 
Assist in Improving Allergic Body Conditions
1.Effective in reducing allergic response IgE secretion. 
2.Effective in promoting immuno IFN-r cells secretion in lungs.

 

Research  Collaboration Results
28 days animal feed safety assessment  Super Laboratory Co., Ltd.               The no-observed-adverse-effect-level (NOAEL) is 2000 mg/kg/day. This dosage is 255 times the recommended dosage for human consumption. 
Genotoxicity assessment  Super Laboratory Co., Ltd.               Negative for gene mutation analysis. 
In vivo micronucleus assay Super Laboratory Co., Ltd.               Negative for micronucleus in rodents. 
In vitro mammalian chromosome aberration test  Super Laboratory Co., Ltd.               Negativetest response.
Immuno regulation- mice trials  Fu Jen Catholic University, Nutritional Science. 1.Effective in promoting IgG production.
2.Effective in regulating T cell cytokine.
Improving allergic body conditions- mice trials Taipei Medical University 1. Effective in reducing allergic response IgE secretion. 
2. Effective in promoting immuno IFN-r cells secretion in lungs.

Clinical human trials

Research purpose   Collaboration  Research topic
L. j EM Chung Shan Medical University Hospital  A randomized open trial for comparing Xyzal and Xyzal with Lactobacillus johnsonii EM in the treatment clinically chronic allergic rhinitis for children age 7 to 12.
L. r MP108 Chung Shan Medical University Hospital  Assess the adjuvant therapy effectiveness and efficiency of Lactobacillus rhamnosusfor treating chronic allergic rhinitis in children. The study was an 8 weeks, double blinded, placebo controlled, and 4 weeks followed-up research.
L. r MP108 Chung Shan Medical University Hospital, Taipei City Hospital Renai Branch  Assess the adjuvant therapy effectiveness and efficiency of Lactobacillus rhamnosusfor treating atopic dermatitis in children of age 4 month to 4 years. The study was an 8 weeks, randomized, double blinded, and placebo controlled research.
L. p  Taichung veterans general hospital  Assess the adjuvant therapy effectiveness and efficiency of Lactobacillus paracaseifor treating chronic allergic rhinitis in children of age 6 to 13 years. The study was a 12 weeks, double blinded, and placebo controlled research.

International journal publication

Journal  Topic  Abstract/Conclusion
Int J Pediatr Otorhinolaryngol. 2012 Jul;76(7):994-1001. A trial of adding Lactobacillus johnsonii EM1 to levocetirizine for treatment of perennial allergic rhinitis in children aged 7-12 years. The 24-week, 2-phase, crossover treatment program showed that levocetirizine plus L.j EM1 was more effective for PAR than levocetirizine and that this difference persisted for at least 3 months after discontinuation of L.j EM1.
Pediatr Neonatol. 2014 Jun;55(3):181-8 Evaluation of the effect of Lactobacillus paracasei (HF.A00232) in children (6-13 years old) with perennial allergic rhinitis: a 12-week, double-blind, randomized, placebo-controlled study. Pediatr Neonatol. 2014 Jun;55(3):181-8 Evaluation of the effect of Lactobacillus paracasei (HF.A00232) in children (6-13 years old) with perennial allergic rhinitis: a 12-week, double-blind, randomized, placebo-controlled study.Dietary supplementation with LP (HF.A00232) provided no additional benefit when used with regular levocetirizine in treating AR in the initial 8 weeks of our study, but there was a continuing decrease in PRQLQ scores, as well as a significant improvement in individual symptoms of sneezing, itchy nose, and swollen eyes, after discontinuing regular levocetirizine treatment.